By Jorge Aura -
The biopharmaceutical sector is living a speculation moment. The general feeling among investors is that great advances with the fight against cancer are going to be produced and the existing medication will be improved. Some companies conduct promising studies against cancer. It is speculated that before 10 years we could have a substantial improvement in the partial cure of the most deadly cancers. Meanwhile, other companies are trying to improve the current medication for the orphan indications and critical care market.
The biopharmaceutical sector is living a speculation moment. The general feeling among investors is that great advances with the fight against cancer are going to be produced and the existing medication will be improved. Some companies conduct promising studies against cancer. It is speculated that before 10 years we could have a substantial improvement in the partial cure of the most deadly cancers. Meanwhile, other companies are trying to improve the current medication for the orphan indications and critical care market.
There are three companies that are making some spectacular progress in their studies. Omeros Corporation (NASDAQ:OMER) and Tenax Therapeutics Inc (TENX).
In the next article I will write about the reasons to take a speculative position in these companies.
1. Omeros Corporation
According google finance, Omeros Corporation is a biopharmaceutical company that is
engaged in discovering, developing and commercializing small-molecule
and protein therapeutics for large-market, as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system. Its marketed drug product, Omidria (phenylephrine and
ketorolac injection), is used during cataract surgery or intraocular
lens (IOL) replacement. Omidria is derived from its PharmacoSurgery
platform, which is designed for patients undergoing ophthalmological,
arthroscopic, urological and other surgical procedures. Its
PharmacoSurgery platform is based on low-dose combinations of the United
States Food and Drug Administration (FDA) approved therapeutic agents
delivered directly to the surgical site throughout the duration of the
procedure to inhibit preemptively inflammation and other problems caused
by surgical trauma, and to provide clinical assistances both during and
after surgery. (Source: Google finance).
Pipeline Portfolio
Next Catalyst
- Phase 3 program for OMS721 in patients with IgA nephropathy.
- Revenues about OMIDRIA® in last quarter financials.
- Revenues about OMIDRIA® in last quarter financials.
Fundamentals Analysis
Short interest
Financials
The company reported the second-quarter financial results on August 8 with the following highlights:
| Revenue | $17.2MM |
| Net Income | ($14.4MM) |
| Cash | $29.7MM |
Chart Analysis
- Rsi marks an oversold. The MACD marks a possible change in upward trend.
2. Tenax Therapeutics Inc
According google finance, Tenax Therapeutics is a specialty pharmaceutical company. The Company is focused on
identifying, developing and commercializing products for the critical
care market. The Company's main product is levosimendan. Levosimendan is
a calcium sensitizer developed for intravenous use in hospitalized
patients with acutely decompensated heart failure. Levosimendan
represents therapeutic modalities for the treatment of Low Cardiac
Output Syndrome (LCOS), septic shock and other critical care conditions.
The therapeutic effects of levosimendan are mediated through increased
cardiac contractility by calcium sensitization of troponin C, resulting
in a positive inotropic effect, which is not associated with substantial
increases in oxygen demand; opening of potassium channels in the
vasculature smooth muscle, resulting in a vasodilatory effect on all
vascular beds, and opening of mitochondrial potassium channels in
cardiomyocytes, resulting in a cardioprotective effect. (Source: Google finance).
Pipeline Portfolio
Next Catalyst
- LEVO-CTS confirmatory trial in cardiac surger.- NDA news about LEVO-CTS.
- Possible partners or collaborations.
Fundamentals Analysis
Financials
The company reported the second-quarter financial results on August 9 with the following highlights:| Revenue | $0MM |
| Net Income | ($2.98MM) |
| Cash | $8.99MM |
Chart Analysis
Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it. Jorge Aura has no business relationship with any company whose stock is mentioned in this article.
